期刊
THERAPEUTIC INNOVATION & REGULATORY SCIENCE
卷 57, 期 4, 页码 865-874出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s43441-023-00518-0
关键词
Signal detection; Evaluation; Causal association; FDA medical queries; Bradford Hill
Safety clinicians have a wealth of resources to perform signal detection, but there are nuances in regulatory approaches and statistical considerations that need to be appreciated. New approaches like FDA Medical Queries emphasize the value of considering medical concepts over individual adverse events. One area that needs further clarity is evaluating the causal relationship between safety signals and the drug of interest. The complexity of this process should be understood to successfully characterize the emerging safety profile of a drug pre-marketing.
Safety clinicians have a wealth of resources describing how to perform signal detection. Nevertheless, there are some nuances concerning approaches taken by regulatory authorities and statistical considerations that should be appreciated. New approaches, such as the FDA Medical Queries, illustrate the value of considering medical concepts over individual adverse events. One area which would benefit from further clarity is how safety signals may be evaluated for evidence of a causal relationship to the drug of interest. Just as such safety signals can take many forms, the types of tools and methods required to interrogate these signals are equally as diverse. An understanding of the complexity of this process can aid the safety reviewer in successfully characterizing the emerging safety profile of a drug during the pre-marketing phase of development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据